Enveric Biosciences Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Invesco S&P 500 Low Volatility ETF trades at $75.6. The key difference: Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | SPLV | |
|---|---|---|
Market Cap | $6.20M | — |
Sector | Health | — |
52-Week High | $17.40 | $77.97 |
52-Week Low | $1.27 | $70.30 |
Enterprise Value | $1.30M | — |
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
SPLV trades at $76.21, down 0.07% with neutral technical signals. The ETF focuses on low-volatility S&P 500 stocks, offering stability amid market uncertainty. Recent news highlights its role in diversification as investors seek shelter from tech sell-offs and geopolitical tensions. Moving averages show a bullish trend, while oscillators indicate neutrality, with RSI at 55.45 suggesting balanced momentum.
Outlook: SPLV provides defensive exposure with historical resilience, but reliance on low-volatility factors may lag in bullish markets. Risks include concentrated sector bets and interest rate sensitivity. Analyst sentiment is mixed, reflecting its niche role in risk-averse portfolios.
Trailing returns across standard periods
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →